These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 26568054)
1. A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis. Wulffraat NM Expert Opin Drug Saf; 2015; 14(12):1961-7. PubMed ID: 26568054 [TBL] [Abstract][Full Text] [Related]
2. Canakinumab for the treatment of active systemic juvenile idiopathic arthritis. Orrock JE; Ilowite NT Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1015-24. PubMed ID: 27367267 [TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of systemic inflammatory diseases in childhood: "Lessons from clinical trials of anti-cytokine monoclonal antibodies for Kawasaki disease, systemic onset juvenile idiopathic arthritis, and cryopyrin-associated periodic fever syndrome". Yokota S; Kikuchi M; Nozawa T; Kanetaka T; Sato T; Yamazaki K; Sakurai N; Hara R; Mori M Mod Rheumatol; 2015 Jan; 25(1):1-10. PubMed ID: 24842480 [TBL] [Abstract][Full Text] [Related]
4. Canakinumab for the treatment of systemic juvenile idiopathic arthritis. Grom AA Expert Rev Clin Immunol; 2014 Nov; 10(11):1427-35. PubMed ID: 25269376 [TBL] [Abstract][Full Text] [Related]
5. Safety of biologic therapies for the treatment of juvenile idiopathic arthritis. Horneff G Expert Opin Drug Saf; 2015 Jul; 14(7):1111-26. PubMed ID: 26084637 [TBL] [Abstract][Full Text] [Related]
6. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes. Church LD; McDermott MF Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548 [TBL] [Abstract][Full Text] [Related]
7. Investigational drugs for treatment of juvenile idiopathic arthritis. Mauro A; Rigante D; Cimaz R Expert Opin Investig Drugs; 2017 Apr; 26(4):381-387. PubMed ID: 28277884 [TBL] [Abstract][Full Text] [Related]
8. Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis. Hoy SM BioDrugs; 2015 Apr; 29(2):133-42. PubMed ID: 25822149 [TBL] [Abstract][Full Text] [Related]
9. Impact of IL1RN Variants on Response to Interleukin-1 Blocking Therapy in Systemic Juvenile Idiopathic Arthritis. Hinze C; Fuehner S; Kessel C; Wittkowski H; Lainka E; Baehr M; Hügle B; Haas JP; Ganser G; Weißbarth-Riedel E; Jansson A; Foell D Arthritis Rheumatol; 2020 Mar; 72(3):499-505. PubMed ID: 31599092 [TBL] [Abstract][Full Text] [Related]
10. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Ruperto N; Quartier P; Wulffraat N; Woo P; Ravelli A; Mouy R; Bader-Meunier B; Vastert SJ; Noseda E; D'Ambrosio D; Lecot J; Chakraborty A; Martini A; Chioato A; Arthritis Rheum; 2012 Feb; 64(2):557-67. PubMed ID: 21953497 [TBL] [Abstract][Full Text] [Related]
11. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ruperto N; Brunner HI; Quartier P; Constantin T; Wulffraat NM; Horneff G; Kasapcopur O; Schneider R; Anton J; Barash J; Berner R; Corona F; Cuttica R; Fouillet-Desjonqueres M; Fischbach M; Foster HE; Foell D; Radominski SC; Ramanan AV; Trauzeddel R; Unsal E; Levy J; Vritzali E; Martini A; Lovell DJ; Ann Rheum Dis; 2018 Dec; 77(12):1710-1719. PubMed ID: 30269054 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Tarp S; Amarilyo G; Foeldvari I; Christensen R; Woo JM; Cohen N; Pope TD; Furst DE Rheumatology (Oxford); 2016 Apr; 55(4):669-79. PubMed ID: 26628580 [TBL] [Abstract][Full Text] [Related]
17. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis. Herlin T Expert Rev Clin Immunol; 2012 Aug; 8(6):517-25. PubMed ID: 22992145 [TBL] [Abstract][Full Text] [Related]
18. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives. Toplak N; Blazina Š; Avčin T Drug Des Devel Ther; 2018; 12():1633-1643. PubMed ID: 29922038 [TBL] [Abstract][Full Text] [Related]
19. Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations. Woerner A; von Scheven-Gête A; Cimaz R; Hofer M Expert Rev Clin Immunol; 2015 May; 11(5):575-88. PubMed ID: 25843554 [TBL] [Abstract][Full Text] [Related]
20. Clinical value of blocking IL-6 receptor. Mima T; Nishimoto N Curr Opin Rheumatol; 2009 May; 21(3):224-30. PubMed ID: 19365268 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]